Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 14/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463661 | 0.85 | HAVCR2 (0.62) | HAVCR2HSD17B10KDM4EXDH | |
| SCHEMBL22988100 | 0.84 | KDM4E (0.78) | HAVCR2HSD17B10ALDH1A1KDM4EPOLB | |
| SCHEMBL404656 | 0.83 | HAVCR2 (0.75) | HAVCR2HSD17B10XDH | |
| SCHEMBL11082526 | 0.83 | HAVCR2 (0.66) | HAVCR2HSD17B10ALDH1A1KDM4EPOLB | |
| SCHEMBL11080162 | 0.83 | HAVCR2 (0.66) | HAVCR2HSD17B10ALDH1A1KDM4EPOLB | |
| SCHEMBL404548 | 0.81 | HAVCR2 (0.80) | HAVCR2HSD17B10 | |
| SCHEMBL11177065 | 0.81 | HSD17B10 (0.66) | HAVCR2HSD17B10ALDH1A1KDM4EHPGD | |
| SCHEMBL404764 | 0.81 | HAVCR2 (1.00) | HAVCR2HSD17B10XDH | |
| SCHEMBL22987507 | 0.80 | KDM4E (0.69) | HAVCR2HSD17B10ALDH1A1KDM4EPOLB | |
| SCHEMBL22987493 | 0.78 | KDM4E (0.73) | HAVCR2HSD17B10ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HAVCR2 84/4885HSD17B10 3443/4885ALDH1A1 1909/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HAVCR2 84/4885HSD17B10 3443/4885ALDH1A1 1909/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HAVCR2 84/4885HSD17B10 3443/4885ALDH1A1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.